AbbVie Posts an Earnings Beat but Forecast Misses as Competition Intensifies | Barron’s
reported quarterly earnings that beat analysts’ estimates but revenue below consensus as sales for many of its drugs declined from the prior year. The company’s full-year earnings forecast also missed estimates.
(ticker: ABBV) reported adjusted fourth-quarter earnings of $3.60 a share on revenue of $15.12 billion, compared to year-earlier profit of $3.08 a share on sales of $14.89 billion. Analysts surveyed by FactSet were expecting earnings of $3.56 a share on sales of $15.33 billion.